Acumen's sabirnetug story is dominated by one late-2026 ALTITUDE-AD readout, a going-concern warning, and a cash runway that may not reach commercial proof.
References
Sources used in this report
SEC issuer filing indexSEC submissions index for Acumen Pharmaceuticals2026-05-13 · CIK, ticker, exchange, SIC, fiscal year end, filing inventory, and latest report dates.SEC company factsSEC XBRL company facts for Acumen Pharmaceuticals2026-05-13 · Cash, marketable securities, expenses, losses, assets, liabilities, equity, and operating cash flow cross-checks.Annual reportAcumen FY2025 Form 10-K2026-03-26 · Business description, sabirnetug program, Phase 1 data, EBD and collaboration context, risks, competition, financials, and going-concern disclosure.Quarterly reportAcumen Q1 FY2026 Form 10-Q2026-05-12 · Latest balance sheet, cash flow, private placement, debt, liquidity, and going-concern disclosure.Company earnings releaseAcumen Q1 FY2026 results release2026-05-12 · Q1 business update, late-2026 ALTITUDE-AD timing, EBD milestone, cash runway, expenses, and net loss.Company earnings releaseAcumen FY2025 results release2026-03-26 · FY2025 financial results, OLE update, private placement context, and EBD milestone.Proxy statementAcumen 2026 DEF 14A2026-04-23 · Annual meeting matters, board nominees, board independence, committee structure, compensation process, and share count.Company current-report exhibitAcumen March 2026 EBD and private placement release2026-03-16 · Private placement, EBD preclinical data, JCR collaboration context, and expected use of proceeds.Government clinical trial registryClinicalTrials.gov NCT063351732026-05-13 · ALTITUDE-AD trial status, enrollment, arms, masking, primary outcome, and estimated completion.FDA official releaseFDA Leqembi traditional approval announcement2023-07-06 · Official context for approved anti-amyloid therapy in early Alzheimer disease.FDA official releaseFDA Kisunla approval announcement2024-07-02 · Official context for approved donanemab competition and Alzheimer disease treatment landscape.